Project Grant R01CA285588
Award Date
6/1/24
Completion Date
5/31/29
Dollars Obligated
$681K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
This Project Grant award of $210,789 from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research to evaluate the effectiveness of a novel antisense therapy (termed CDKKMO) targeting the DKK-1 protein in treating osteosarcoma (OS) in dogs. The research aims to empirically characterize the molecular mechanisms governing the effects of DKK-1 inhibition on OS tumor progression, metastasis, and bone destruction in canine OS cell lines and patient-derived...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $1,825,646 to Virginia Polytechnic Institute & State University (Virginia Tech) to develop an integrated image-guided histotripsy system for the non-invasive treatment of heterogeneous osteosarcoma (OS) tumors. The key objectives are to: 1) Design and construct a histotripsy system with 3D cavitation imaging and image-fusion targeting capabilities; 2) Develop...
This $399,200 Project Grant awarded by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) will support the development and evaluation of 111In-dinutuximab-IR800, a dual-labeled molecular imaging agent for intraoperative detection of metastatic osteosarcoma lesions. The University of Pittsburgh will optimize the manufacturing, pharmacology, toxicology, and stability of the imaging agent to enable clinical translation. They will also test the agent's ability to detect...
This $452,549 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research by Emory University to comprehensively characterize the intrinsic molecular features and extrinsic tumor microenvironment of MYC-driven osteosarcoma. The key objectives are to: Identify the cross-species molecular signatures and cell-cell communications in MYC-hyperactivated human and murine osteosarcoma tumors. This will involve profiling intrinsic and...
This $581,723 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Johns Hopkins University will fund the development of a novel hyperspectral single-photon emission microscope system called "Alpha-Scope" for in vivo 3D autoradiography of radiopharmaceuticals and their radioactive daughter radionuclides in small animal models. The advanced imaging system will utilize a novel CZT spectrometer to provide high-resolution, high-sensitivity...
This $514,405 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Sanford Research aims to investigate the role of cancer-dependent skeletal genes and pathways in osteosarcoma progression. The research will utilize genetically engineered mouse models developed by the organization to understand how cancer-dependent pathways involving tumor protein p53 and Rb mutations contribute to the development and metastasis of osteosarcoma, a fatal bone tumor...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to Northwestern University to conduct research aimed at enhancing the effectiveness of adoptive natural killer (NK) cell therapy for treating solid tumors, such as canine soft tissue sarcomas. The key objectives are: 1) Determining the safe and effective dose of the MIC-targeting antibody B10G5 in activating endogenous NK cells and reshaping the tumor microenvironment; 2)...
The Department of the Army Medical Command awarded a $1,750,524 project grant to Dana-Farber Cancer Institute, Inc. for research on treatment options for metastatic osteosarcoma. The grant was awarded on August 1, 2022 under the Military Medical Research and Development program (CFDA 12.420) and will support research through July 31, 2025. The Military Medical Research and Development program aims to transform health care for service members and the public through innovative biomedical research....
The National Cancer Institute (NCI) awarded a $738,698 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the Beckman Research Institute of the City of Hope in Duarte, California. The project will investigate combining targeted alpha therapy (TAT) using anti-CD38 radiolabeled antibody 225Ac-DOTA-daratumumab with total marrow irradiation (TMLI) and a reduced-intensity conditioning (RIC) regimen for the treatment of relapsed/refractory acute myelogenous leukemia (AML) in patients over 60...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $545,078 to The Johns Hopkins University to conduct research aimed at enhancing the efficacy of radiopharmaceutical therapy for prostate cancer (PC) and renal cell carcinoma (RCC). The research will systematically evaluate the effect of prostate-specific membrane antigen (PSMA)-based radiopharmaceutical therapy on glutaminolysis, a critical metabolic pathway in these cancer...